20 results about "Ototoxicity" patented technology

The invention belongs to the field of biological medicine research and development, discloses a method and a system for collecting and analyzing auditory electrophysiological data of experimental animals, and is particularly suitable for non-human primates. The method comprises the following steps: delivering a drug to a middle ear cavity through an external auditory canal, and synchronously recording auditory electrophysiological data before and after drug administration; aBR and DPOAE multi-mode detection is adopted, and the frequency range of 4 kHz to 32 kHz is covered; setting anesthesia depth and three-electrode positioning to reduce interference; optimizing the signal-to-noise ratio through noise suppression and dynamic signal superposition; an auditory threshold database is constructed, and a machine learning model is combined to judge an injured part. The system integrates a multi-modal stimulation module, a minimally invasive drug delivery device and a data analysis platform, and supports cross-species data compatibility. The accuracy of otology medicine research is remarkably improved, the surgical operation risk is avoided, and the method is suitable for gene therapy, ototoxicity screening and other scenes.

The invention discloses application of tangeretin in preparation of a medicine for treating hearing loss. The invention proposes and verifies that the tangeretin can effectively protect the spiral ganglion neurons for the first time, and avoids the death of the cells caused by cisplatin medication; experimental data show that the preventive tangeretin drug can effectively prevent hearing loss of adult mice and greatly relieve sensorineural deafness caused by cis-platinum, and a new thought is provided for clinical ototoxicity drug administration.

Disclosed is a method of impeding platinum-based chemotherapeutic induced ototoxicity, and / or other toxicity, the method comprising administering a colony stimulating factor 1 receptor (CSF1R) inhibitor to a subject in an amount sufficient to impede ototoxicity, and / or other toxicity, inducible by a platinum-based chemotherapeutic; and administering the platinum-based chemotherapeutic to the subject. The CSF1R inhibitor can be, for example, pexidartinib. The platinum-based chemotherapeutic can be, for example, cisplatin. Compositions, medicaments, kits, and uses are disclosed related to the same. Further, a method of screening for a compound able to impede a platinum-based chemotherapeutic induced toxicity is disclosed.

Methods and compositions are disclosed for reducing neuropathy or ototoxicity associated with chemotherapeutic agents by administering one or more enol compounds to a subject.

Methods and compositions are disclosed for reducing neuropathy or ototoxicity associated with chemotherapeutic agents by administering one or more enol compounds to a subject.

The present invention provides derivatives of quinolylnitrones of formula I, wherein the meaning of the substituents is as described in the description, useful in treatment and / or prevention of hearing loss.Advantageously, these quinolylnitrones of formula (I) have a broad-spectrum effect, being efficient in the prevention and treatment of hearing loss regardless of its origin, whether caused by a physical agent, such as noise, or an ototoxic agent such as H2O2.

Methods for making and using hydrogels comprising therapeutic microparticle compositions are disclosed. Illustrative methods of the invention include methods of making a hydrogel composition, the method comprising combining at least 14% w / v of a non-ionic copolymer surfactant having the linear formula (C3H6OꞏC2H4O)x; microparticles comprising a polycaprolactone; and a therapeutic agent; such that the hydrogel composition is made. Embodiments of the invention further include compositions made by the methods disclosure herein as well as methods for using these compositions. For example, methods of the invention include disposing a composition in the ear of a subject being administered cisplatin, wherein amounts of the composition administered are sufficient to preserve hearing function in a mouse model of cisplatin ototoxicity.

The present application relates to the technical field of biological medicine, and particularly relates to a composition for protecting cochlear spiral ganglion neurons and application thereof. The composition comprises Panax notoginseng saponins (PNS) and Polygonatum sibiricum polysaccharide (PSP). Research shows that the composition can significantly improve the survival rate of neurons, promote neurite growth, reduce the level of reactive oxygen species, inhibit cell apoptosis, and promote autophagy by regulating the PI3K / AKT signaling pathway, thereby effectively resisting ototoxicity damage induced by aminoglycoside antibiotics. The present application further provides the use of the composition in the preparation of a drug for preventing or treating sensorineural hearing loss.

The present invention relates to an amino acid-modified compound comprising a pillararene moiety, a linker having a divalent triazole ring, and an amino acid-modified group, a method for preparing the same, and a use thereof. The amino acid-modified compound of the present invention can be obtained in a simple and high-yield synthesis method, and the amino acid-modified compound is capable of spontaneously fusing into a cell membrane, exhibits high water transport efficiency and selectivity, is capable of significantly accelerating cell migration, and has excellent eardrum repair ability, and has low ototoxicity.

The invention provides an application of an expression inhibitor of Gadd45a in preparation of a medicine for preventing or reducing the ototoxicity of cis-platinum. In-vivo and in-vitro experiments prove that by locally applying the Gadd45a inhibitor, cochlea hair cells and auditory functions can be effectively protected by activating autophagy, inhibiting an NF-kappaB1 inflammation pathway and regulating JNK-mediated apoptosis, so that hearing loss caused by cis-platinum is relieved. The invention provides a brand-new effective medicine product and a treatment strategy for clinically preventing and treating the ototoxicity of cis-platinum, and has important clinical application value for preventing or relieving the ototoxicity of a patient receiving cis-platinum chemotherapy.

A method of treating and / or reducing ototoxicity caused by a chemotherapeutic agent in a mammalian subject, comprising administering to the subject a therapeutically effective amount of a chemotherapeutic agent, and administering to the subject a therapeutically effective amount of a pentaaza macrocyclic ring complex corresponding to the Formula (I) below, prior to, concomitantly with, or after administration of the chemotherapeutic agent, whereby ototoxicity of the chemotherapeutic agent is decreased:

The invention relates to the field of medical application of biological hydrogel, in particular to dexamethasone loaded hydrogel delivered across tympanic membranes and a preparation method of the dexamethasone loaded hydrogel, the hydrogel takes gelatin Gel and dopamine modified hyaluronic acid HADA as base materials, a three-dimensional network structure is formed through enzymatic crosslinking of transglutaminase mTGase, dexamethasone sodium phosphate Dex is loaded, and the hydrogel can be used for preparing the dexamethasone loaded hydrogel. Furthermore, local trans-tympanic membrane middle ear drug delivery and release are realized; specifically, a solution A composed of Gel, HADA and Dex and a solution B composed of mTGase are evenly mixed according to the volume ratio of 4: 1 and dropwise added to the surface of the tympanic membrane through an external auditory canal, and finally Gel-HADA-Dex hydrogel is formed on the surface of the tympanic membrane. Local precise high-concentration drug delivery can be achieved, systemic drug toxicity is avoided, materials are safe, ear toxicity is avoided, meanwhile, adhesion performance is high, drug release is continuous, gradual self-degradation is achieved, manual taking out is not needed, and use convenience is remarkably improved.

The invention belongs to the field of biological pharmacy, and particularly relates to application of maslinic acid as a cis-platinum toxicity protective agent. The maslinic acid disclosed by the invention can be used for preventing ototoxicity induced by cis-platinum by recovering the activity of mouse cochlear hair cells SLC7A11, and can be used for repairing mouse hearing impairment induced by cis-platinum. Experimental results show that maslinic acid can recover activity reduction of SLC7A11 caused by cis-platinum, so that the level of LPO in cells is reduced, the survival rate of HEI-OC1 cells is increased, and the anti-cancer effect of cis-platinum is not affected; animal experiments also show that maslinic acid can inhibit mouse hearing impairment induced by cis-platinum. Therefore, maslinic acid can reduce the ear toxicity of cis-platinum and exert an inner ear protection effect.

The invention relates to the technical field related to medical medicines, discloses application of glycyrrhizic acid in inhibiting ototoxicity caused by cis-platinum chemotherapy, and aims to provide novel medical application of glycyrrhizic acid, namely the glycyrrhizic acid can be used for reducing ototoxicity side effects caused by CDDP. After a C57BL6 / J mouse is administered according to a model, ABR waveform of a CDDP group mouse is disordered, a hearing threshold is obviously increased, and an I-wave incubation period is prolonged; after the GL is given to the mouse, ABR waveform differentiation of each frequency is good, the hearing threshold value is obviously reduced, and the I-wave incubation period is shortened. Hamp, Hamp; e staining results show that CDDP destroys the morphological structure of cochlear vascular lines, resulting in cytoplasm reduction, vacuole increase, cell nucleus fixation and constriction and boundary fuzziness; the GL intervention enables the whole cytoplasm of the cochlea vascular lines of the mouse to be fuller, the vacuoles to be obviously reduced, the cell nucleus to be complete and the boundary to be clearer, which indicates that the GL inhibits the cochlea vascular line injury caused by the CDDP. EB staining finds that red fluorescence in the CDDP group microvessels is weak, and a large amount of EB exudes, which prompts that the permeability of BLB is increased.

The invention relates to a ciprofloxacin dry powder inhalation particle, the dry powder inhalation particle comprises 60-95% by weight of ciprofloxacin hydrochloride and a pharmaceutically acceptable carrier, the mass median aerodynamic diameter (MMAD) of the dry powder inhalation particle is 1-5 [mu] m, and the geometric particle size distribution is that D10 is less than or equal to 2.0 [mu] m, D50 is less than or equal to 4.5 [mu] m, and D90 is less than or equal to 8.0 [mu] m. The dry powder inhalation particle can target high-concentration deposition of a lung infection part, the bioavailability is remarkably improved, and risks of renal toxicity, ototoxicity, drug resistance and the like are reduced.

The application belongs to the field of biological pharmacy, and particularly relates to application of maslinic acid as a cisplatin ototoxicity protective agent. The application discloses that maslinic acid can prevent cisplatin-induced ototoxicity by restoring the activity of mouse cochlea hair cells SLC7A11, and can repair cisplatin-induced hearing impairment in mice. Experimental results show that maslinic acid can restore the reduced activity of SLC7A11 caused by cisplatin, thereby reducing the intracellular LPO level, increasing the HEI-OC1 cell survival rate, and not affecting the anticancer effect of cisplatin; animal experiments also show that maslinic acid can inhibit cisplatin-induced hearing impairment in mice. Therefore, maslinic acid can reduce the ototoxicity of cisplatin and play an inner ear protection role.

The invention discloses an antioxidant nano-drug for relieving ototoxicity of cis-platinum and a preparation method of the antioxidant nano-drug. The antioxidant nano-drug is obtained by carrying out Mannich condensation reaction on epigallocatechin gallate, D-methionine and formaldehyde in the presence of polyoxyethylene polyoxypropylene ether F127, and the components in the antioxidant nano-drug are uniformly distributed. The antioxidant nano-drug provided by the invention retains the antioxidant properties of EGCG and D-Met, is small and uniform in size and strong in stability, and is beneficial to entering cells to exert the efficacy, and an in-vitro cell experiment proves that the antioxidant nano-drug has a stronger effect of relieving the toxicity of cis-platinum under the equivalent concentration compared with a small molecular drug.

The invention belongs to the field of medical application, and particularly relates to application of troxerutin in a medicine for preventing and treating ototoxicity induced by cis-platinum. The invention provides an application of troxerutin in a medicine for preventing and treating ototoxicity induced by cis-platinum, research finds that troxerutin can remarkably inhibit ROS accumulation, Fe overload and GPX4 reduction induced by cis-platinum, so that excessive accumulation of active oxygen and ferroptosis in hair cells are blocked, the auditory function is improved, troxerutin remarkably inhibits cell apoptosis induced by cis-platinum, and the troxerutin can be used for preventing and treating ototoxicity induced by cis-platinum. And a new way is provided for transformation application of traditional Chinese medicine micromolecules in ear toxicity prevention and treatment.

The application discloses an application of an aldose reductase inhibitor to preparation of a drug for treating or preventing drug-induced deafness. The aldose reductase inhibitor is applied to prevention or treatment of drug-induced deafness for the first time in the application. Experiments show that the aldose reductase inhibitor can reduce cisplatin-induced increase of aldose reductase activity. In the application, epalrestat and cisplatin are co-cultured in cochlear explants, and it is found that epalrestat of different concentrations (10 / 50 / 100 μM) has a protective effect on hair cell damage caused by cisplatin. The epalrestat is used in a cisplatin acute ototoxicity model of mice, and can relieve cisplatin-induced hearing loss. It is also found that gomisin, as a new aldose reductase inhibitor, also has the performance of relieving cisplatin-induced hearing loss. Specifically, when gomisin is applied to in vitro culture of newborn mouse cochlea, the gomisin shows a protective effect on cochlear hair cells (HCs) and spiral neuron ganglion (SGN) in P2 newborn mouse cochlear in vitro culture.

The invention discloses application of targeted inhibition of PPP1CB in preparation of medicines for preventing and treating ototoxicity of platinum medicines, and belongs to the technical field of gene engineering. In the first aspect, the invention relates to a nucleic acid which comprises shRNA (short hairpin Ribonucleic Acid) for knocking down a Ppp1cb gene, and the nucleotide sequence of the shRNA is SEQ ID NO.1. On the second aspect, the invention relates to a reagent capable of inhibiting Ppp1cb gene expression or PPP1CB protein activity, and application of the reagent in preparation of drugs for treating or preventing ototoxicity of platinum drugs. The invention reveals that the impaired SGNs and hair cells can be effectively reduced by inhibiting the expression of PPP1CB so as to prevent or treat the drug-induced hearing impairment caused by cis-platinum, no side effect is generated, and the application potential in clinical treatment of patients with the drug-induced hearing impairment is higher.